MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that lots of patients had stopped taking Amgen’s experimental weight loss shot ...

A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body weight over a year, ... Over 12 weeks, average weight loss was 11.3%, ...

In the obesity-diabetes cohort, weight loss ranged from -8.4% to -12.3% with MariTide and was -1.7% with placebo. “A weight plateau was not reached at 52 weeks, with weight continuing a downward ...

The researchers working on MariTide are currently preparing for a 72-week phase 3 trial, and evaluating if the drug can help people lose more weight than the ~16% they shed in the phase II trial.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

MariTide led to around 20% weight loss in obesity without diabetes vs. 2.6% with placebo. Amgen begins a 72-week Phase 3 MariTide trial, targeting obesity and comorbidities, including heart ...